Clinical trialNCT04905810RecruitingPhase 2Interventional

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

SponsorBrian JonasEnrollment20Acute Myeloid LeukemiaRecurrent Acute Myeloid Leukemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial evaluates the effect of azacitidine or decitabine and venetoclax in treating patients with acute myeloid leukemia that has not been treated before (treatment naive) or has come back (relapsed). Chemotherapy drugs, such as azacitidine, decitabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Brian A Jonas
University of California, Davis
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ucsf-Fresno
Clovis, California, United States
Mohammed Bukari, MD
Recruiting
Ucla / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Caspian Oliai
Not, yet, recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Brian A. Jonas
Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Matthew J. Wieduwilt
Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azacitidine →Decitabine →Venetoclax →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 9 Feb 2022
Primary completion: 1 May 2025
Completion: 1 Dec 2025
Last update posted: 29 May 2024
Registered enrollment: 20
Registry id: NCT04905810

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.